<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302768</url>
  </required_header>
  <id_info>
    <org_study_id>SELENIO 2012</org_study_id>
    <nct_id>NCT02302768</nct_id>
  </id_info>
  <brief_title>Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT</brief_title>
  <official_title>Effect of Supplementation of Two Doses of L-selenomethionine (Semet; 80 and 160 mcg) Versus Placebo in Patients With Chronic Autoimmune Thyroiditis (AIT) With Normal Thyroid Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Siena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Siena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the past 10 years, several clinical studies have suggested that selenium supplementation
      may influence the natural history of AIT. Recently, Interferon gamma (IFNγ)-inducible
      chemokines (CXCL-9, -10 and -11) were shown to be elevated in the AIT patients. The aim of
      this prospective, randomized, controlled study is to evaluate the effect of two different
      doses of selenomethionine (80 or 160 mcg) versus placebo in euthyroid women with AIT, in
      terms of reduction of anti-thyroid antibodies and improvement of thyroid hypoechogenicity,
      over 24 months. Serum levels of selenium, CXCL-9, -10 and -11 and their regulators, Tumor
      necrosis factor alpha (TNFα) and INFγ, thyroid function and volume and the quality of life of
      AIT patients are also evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of anti-thyroid antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Anti thyroperoxidase and thyroglobulin antibodies are measured by a chemiluminescent assay. Any statistically significant decrease of one or both antibody values compared to the baseline is considered a reduction relevant to the study outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of thyroid echogenicity</measure>
    <time_frame>12 months</time_frame>
    <description>High-resolution sonograhic images are captured, converted into a spectrum of gray-scale pixels (gsp) ranging from 0 (lowest echogenicity) to 255 (highest echogenicity) and a mean value is then obtained. Any statistically significant increase of the gsp compared to the baseline is considered an improvement relevant to the study outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention or reduction of the incidence of hypothyroidism</measure>
    <time_frame>24 months</time_frame>
    <description>Defined by a significant lower number of new subclinical or overt hypothyroidism cases in the two Semet groups compared to the placebo group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Thyroiditis Autoimmune</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80-Semet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive selenomethionine at 80 mcg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>160-Semet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to receive selenomethionine at 160 mcg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Selenomethionine</intervention_name>
    <arm_group_label>80-Semet</arm_group_label>
    <arm_group_label>160-Semet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic autoimmune thyroiditis defined by positivity of anti
             thyroperoxidase and/or anti thyroglobulin antibodies (&gt; or = 100 U/l) and thyroid
             hypoechogenicity

        Exclusion Criteria:

          -  Presence of other thyroid disease but micronodules

          -  History of the malignancy in the past 5 years

          -  Drugs affecting immune system and/or thyroid function

          -  Pregnancy detected during screening or follow-up.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Furio Pacini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Siena</affiliation>
  </overall_official>
  <reference>
    <citation>Rayman MP. Selenium and human health. Lancet. 2012 Mar 31;379(9822):1256-68. doi: 10.1016/S0140-6736(11)61452-9. Epub 2012 Feb 29. Review.</citation>
    <PMID>22381456</PMID>
  </reference>
  <reference>
    <citation>Nacamulli D, Petricca D, Mian C. Selenium and autoimmune thyroiditis. J Endocrinol Invest. 2013 Nov;36(10 Suppl):8-14.</citation>
    <PMID>24419054</PMID>
  </reference>
  <reference>
    <citation>Rotondi M, Chiovato L. The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interferon-γ inducible chemokines and their receptor. Curr Pharm Des. 2011;17(29):3202-16. Review.</citation>
    <PMID>21864266</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Siena</investigator_affiliation>
    <investigator_full_name>Furio Pacini</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Thyroiditis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

